The peptide problem: Hype is outrunning the evidence
medicalxpress - Health Canada recently warned Canadians not to buy or inject unauthorized peptide drugs sold online, naming products that include BPC-157, CJC-1295, ipamorelin, TB-500 and retatrutide.
AI Summary: The booming market for peptide therapies and supplements is racing past the science. Researchers report limited clinical evidence, unclear long-term safety, and weak regulatory oversight, while consumer demand and marketing hype surge. Clinicians urge caution: biological plausibility isn’t the same as proven benefit, and enthusiasm should not substitute for rigorous trials.
Related Stories
Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 2 months
US gray‑market peptides face scrutiny as FDA panel debate looms / 6 days
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 7 wks
Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 2 months
Denali drug receives accelerated approval for rare CNS indication / 3 months
FDA backs three psychedelic studies with special commissioner vouchers / 2 months
FDA clears first once‑weekly basal insulin for Type 2 diabetes / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Autism, Pfizer, Genetics, Neuroscience and look for the RSS link.
StackHealth Time Machine